ME03757B - Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti - Google Patents
Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolestiInfo
- Publication number
- ME03757B ME03757B MEP-2020-126A MEP2020126A ME03757B ME 03757 B ME03757 B ME 03757B ME P2020126 A MEP2020126 A ME P2020126A ME 03757 B ME03757 B ME 03757B
- Authority
- ME
- Montenegro
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- formula
- iii
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 28
- 239000000651 prodrug Substances 0.000 title claims 3
- 229940002612 prodrug Drugs 0.000 title claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 208000010643 digestive system disease Diseases 0.000 title 1
- 208000018685 gastrointestinal system disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims 19
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 208000017189 Gastrointestinal inflammatory disease Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 239000004012 Tofacitinib Substances 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- -1 cyano, hydroxy Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims 3
- 229960001350 tofacitinib Drugs 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000002429 large intestine Anatomy 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 102000053187 Glucuronidase Human genes 0.000 claims 1
- 108010060309 Glucuronidase Proteins 0.000 claims 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229930182480 glucuronide Natural products 0.000 claims 1
- 150000008134 glucuronides Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
- C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562259273P | 2015-11-24 | 2015-11-24 | |
| PCT/US2016/063254 WO2017091544A1 (en) | 2015-11-24 | 2016-11-22 | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
| EP16808876.3A EP3380486B1 (en) | 2015-11-24 | 2016-11-22 | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03757B true ME03757B (me) | 2021-04-20 |
Family
ID=57518004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-126A ME03757B (me) | 2015-11-24 | 2016-11-22 | Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US10435428B2 (OSRAM) |
| EP (1) | EP3380486B1 (OSRAM) |
| JP (2) | JP6778747B2 (OSRAM) |
| KR (1) | KR20180080330A (OSRAM) |
| CN (1) | CN108290918B (OSRAM) |
| AU (1) | AU2016359494B2 (OSRAM) |
| BR (1) | BR112018010650A8 (OSRAM) |
| CA (1) | CA3003283A1 (OSRAM) |
| CL (1) | CL2018001345A1 (OSRAM) |
| CO (1) | CO2018005327A2 (OSRAM) |
| CY (1) | CY1122918T1 (OSRAM) |
| DK (1) | DK3380486T3 (OSRAM) |
| EA (1) | EA035816B1 (OSRAM) |
| ES (1) | ES2784523T3 (OSRAM) |
| HR (1) | HRP20200561T1 (OSRAM) |
| HU (1) | HUE049775T2 (OSRAM) |
| IL (1) | IL259076B (OSRAM) |
| LT (1) | LT3380486T (OSRAM) |
| ME (1) | ME03757B (OSRAM) |
| MX (1) | MX383107B (OSRAM) |
| MY (1) | MY189979A (OSRAM) |
| NZ (1) | NZ742574A (OSRAM) |
| PH (1) | PH12018501037A1 (OSRAM) |
| PL (1) | PL3380486T3 (OSRAM) |
| PT (1) | PT3380486T (OSRAM) |
| RS (1) | RS60237B1 (OSRAM) |
| SG (1) | SG11201803686UA (OSRAM) |
| SI (1) | SI3380486T1 (OSRAM) |
| SM (1) | SMT202000242T1 (OSRAM) |
| TW (1) | TWI703147B (OSRAM) |
| UA (1) | UA121270C2 (OSRAM) |
| WO (1) | WO2017091544A1 (OSRAM) |
| ZA (1) | ZA201802967B (OSRAM) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017077288A1 (en) | 2015-11-03 | 2017-05-11 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| EP3712152B1 (en) | 2015-11-03 | 2021-01-13 | Topivert Pharma Limited | 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors |
| CA3003283A1 (en) | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
| FR3060567B1 (fr) * | 2016-12-19 | 2019-05-24 | Ecole Normale Superieure De Lyon | Substrat de glycosidase fluorogene et procede de detection associe |
| CN110418796A (zh) * | 2017-03-08 | 2019-11-05 | 施万生物制药研发Ip有限责任公司 | 托法替尼(tofacitinib)的葡萄糖苷酸前药 |
| US10233174B2 (en) * | 2017-05-23 | 2019-03-19 | Theravance Biopharma R&D Ip, Llc | Thiocarbamate prodrugs of tofacitinib |
| MX2019014054A (es) | 2017-05-23 | 2020-02-05 | Theravance Biopharma R&D Ip Llc | Profarmacos de glucuronida de inhibidores de la cinasa janus. |
| AU2018281327A1 (en) * | 2017-06-05 | 2019-12-05 | Flagship Pioneering Innovations V, Inc. | Multibiotic agents and methods of using the same |
| MA51524A (fr) | 2018-01-05 | 2020-11-11 | Cybrexa 1 Inc | Composés, compositions et méthodes pour le traitement de maladies impliquant des tissus malades acides ou hypoxiques |
| WO2019182322A1 (ko) * | 2018-03-20 | 2019-09-26 | 삼진제약주식회사 | 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물 |
| US12171764B2 (en) | 2018-06-20 | 2024-12-24 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor |
| CN111094314B (zh) * | 2018-08-15 | 2022-08-12 | 江苏豪森药业集团有限公司 | 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用 |
| WO2020051378A1 (en) * | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
| CN109134564B (zh) * | 2018-09-21 | 2022-03-11 | 合肥锐思生物医药有限公司 | 乳果糖糖苷衍生物、其制备方法及其用途 |
| CN113316647A (zh) * | 2018-11-15 | 2021-08-27 | 詹森生物科技公司 | 用于预测对炎性肠病疗法的反应的方法和组合物 |
| PH12021551455A1 (en) | 2018-12-19 | 2022-04-18 | Incyte Corp | Jak1 pathway inhibitors for the treatment of gastrointestinal disease |
| KR20210142154A (ko) | 2019-03-21 | 2021-11-24 | 옹쎄오 | 암 치료를 위한 키나제 억제제와 조합된 dbait 분자 |
| US11634508B2 (en) | 2019-07-10 | 2023-04-25 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
| CN114302744B (zh) | 2019-07-10 | 2025-08-26 | 赛博克萨3公司 | 作为治疗剂的微管靶向剂的肽缀合物 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021097074A1 (en) * | 2019-11-13 | 2021-05-20 | New York University | Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021174024A1 (en) * | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| TW202207918A (zh) | 2020-05-14 | 2022-03-01 | 美商施萬生物製藥研發Ｉｐ有限責任公司 | 腸道選擇性ｊａｋ３抑制劑的投與 |
| CN113943312A (zh) * | 2020-07-17 | 2022-01-18 | 轶诺(浙江)药业有限公司 | 一类肠道裂解型共药及其制备和用途 |
| EP4232146A4 (en) * | 2020-10-22 | 2024-07-31 | Biora Therapeutics, Inc. | METHODS OF TREATMENT AND PREDICTION OF NON-RESPONSE TO ANTI-TNF TREATMENT IN PERSONS WITH GASTROINTESTINAL TRACT DISEASES |
| US20240307396A1 (en) * | 2021-06-07 | 2024-09-19 | The Regents Of The University Of California | Compositions and methods for treating celiac disease |
| EP4357346A4 (en) * | 2021-07-20 | 2025-06-11 | Coval Biopharma (Shanghai) Co., Ltd. | EXTERNAL ANTI-INFLAMMATORY AGENT COUPLING A COMPOUND AND A DRUG, PREPARATION METHOD THEREFOR AND USE THEREOF |
| US20230381185A1 (en) * | 2022-05-14 | 2023-11-30 | 3-D Matrix, Ltd. | Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract |
| CN115073543B (zh) * | 2022-07-20 | 2022-11-15 | 北京普祺医药科技股份有限公司 | 一种jak抑制剂的化合物前药及其制备与应用 |
| CN117567460A (zh) * | 2022-08-08 | 2024-02-20 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| JP2025527481A (ja) | 2022-08-17 | 2025-08-22 | トランセンド セラピューティクス，インコーポレイテッド | フェネチルアミンおよびカチノン前駆体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993022334A1 (en) | 1992-05-04 | 1993-11-11 | Sri International | Pharmaceutical compositions and methods for colonic delivery of corticosteroids |
| US5811388A (en) | 1995-06-07 | 1998-09-22 | Cibus Pharmaceutical, Inc. | Delivery of drugs to the lower GI tract |
| UA72290C2 (uk) | 1999-12-10 | 2005-02-15 | Пфайзер Продактс Інк. | СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ) |
| KR101921850B1 (ko) | 2009-10-09 | 2018-11-23 | 인사이트 홀딩스 코포레이션 | 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체 |
| WO2011079249A2 (en) | 2009-12-23 | 2011-06-30 | Glycomyr, Inc. | Use of vitamin d glycosides and sulfates for treatment of disease |
| WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| JP2013518882A (ja) * | 2010-02-05 | 2013-05-23 | ファイザー・インク | ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物 |
| US20130109720A1 (en) | 2011-11-01 | 2013-05-02 | Hoffmann-La Roche Inc. | Indole inhibitors of crac |
| WO2014194195A2 (en) * | 2013-05-31 | 2014-12-04 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for the therapeutic delivery |
| ES2742179T3 (es) * | 2014-06-24 | 2020-02-13 | Inst Nat Sante Rech Med | Composiciones farmacéuticas que comprenden agonistas del receptor de orexina-1 OX1R para el tratamiento de enfermedades inflamatorias del intestino |
| CA3003283A1 (en) | 2015-11-24 | 2017-06-01 | Theravance Biopharma R&D Ip, Llc | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease |
| EP3394080B1 (en) | 2015-12-23 | 2023-06-07 | The University Of British Columbia | Lipid-linked prodrugs |
| CN106496233B (zh) | 2016-09-26 | 2018-05-15 | 东南大学 | 吡咯并嘧啶类化合物、其制备方法及其用途 |
-
2016
- 2016-11-22 CA CA3003283A patent/CA3003283A1/en not_active Abandoned
- 2016-11-22 HU HUE16808876A patent/HUE049775T2/hu unknown
- 2016-11-22 TW TW105138180A patent/TWI703147B/zh not_active IP Right Cessation
- 2016-11-22 LT LTEP16808876.3T patent/LT3380486T/lt unknown
- 2016-11-22 NZ NZ742574A patent/NZ742574A/en not_active IP Right Cessation
- 2016-11-22 EA EA201891248A patent/EA035816B1/ru unknown
- 2016-11-22 HR HRP20200561TT patent/HRP20200561T1/hr unknown
- 2016-11-22 RS RS20200508A patent/RS60237B1/sr unknown
- 2016-11-22 KR KR1020187017879A patent/KR20180080330A/ko not_active Withdrawn
- 2016-11-22 MX MX2018006282A patent/MX383107B/es unknown
- 2016-11-22 PL PL16808876T patent/PL3380486T3/pl unknown
- 2016-11-22 WO PCT/US2016/063254 patent/WO2017091544A1/en not_active Ceased
- 2016-11-22 BR BR112018010650A patent/BR112018010650A8/pt not_active IP Right Cessation
- 2016-11-22 AU AU2016359494A patent/AU2016359494B2/en not_active Ceased
- 2016-11-22 DK DK16808876.3T patent/DK3380486T3/da active
- 2016-11-22 CN CN201680068165.XA patent/CN108290918B/zh active Active
- 2016-11-22 JP JP2018526682A patent/JP6778747B2/ja active Active
- 2016-11-22 ME MEP-2020-126A patent/ME03757B/me unknown
- 2016-11-22 UA UAA201806963A patent/UA121270C2/uk unknown
- 2016-11-22 MY MYPI2018701637A patent/MY189979A/en unknown
- 2016-11-22 PT PT168088763T patent/PT3380486T/pt unknown
- 2016-11-22 SM SM20200242T patent/SMT202000242T1/it unknown
- 2016-11-22 US US15/358,462 patent/US10435428B2/en active Active
- 2016-11-22 ES ES16808876T patent/ES2784523T3/es active Active
- 2016-11-22 SG SG11201803686UA patent/SG11201803686UA/en unknown
- 2016-11-22 EP EP16808876.3A patent/EP3380486B1/en active Active
- 2016-11-22 SI SI201630741T patent/SI3380486T1/sl unknown
-
2018
- 2018-05-01 IL IL259076A patent/IL259076B/en active IP Right Grant
- 2018-05-07 ZA ZA2018/02967A patent/ZA201802967B/en unknown
- 2018-05-15 PH PH12018501037A patent/PH12018501037A1/en unknown
- 2018-05-18 CL CL2018001345A patent/CL2018001345A1/es unknown
- 2018-05-22 CO CONC2018/0005327A patent/CO2018005327A2/es unknown
-
2019
- 2019-08-29 US US16/555,222 patent/US10961267B2/en active Active
-
2020
- 2020-05-13 CY CY20201100447T patent/CY1122918T1/el unknown
- 2020-08-25 JP JP2020141651A patent/JP2020196742A/ja active Pending
-
2021
- 2021-02-22 US US17/249,126 patent/US11608354B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03757B (me) | Prolekovi jaki inhibitornih jedinjenja za lečenje gastorintestinalne inflamatorne bolesti | |
| HRP20200648T1 (hr) | Derivati sulfamoilpirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b | |
| PH12018500147A1 (en) | Benzodiazepine derivatives as rsv inhibitors | |
| WO2016077464A8 (en) | Amino acid derivatives and their uses | |
| WO2016134301A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| PH12014501283A1 (en) | 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| HRP20241197T1 (hr) | Makrociklični spojevi i primjene istih | |
| BR112013005888A2 (pt) | análogos de carba-nucleosídeo 2'-flúor substituídos para o tratamento antiviral | |
| WO2017123884A8 (en) | Heterocyclic compounds as rsv inhibitors | |
| BR112012017382A2 (pt) | compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica | |
| JP2016530314A5 (OSRAM) | ||
| MY172924A (en) | Neprilysin inhibitors | |
| BR112017011941A2 (pt) | compostos 5-amino-6h-tiazol [4,5-d] pirimidina-2,7-diona substituídos 3 para o tratamento e profilaxia de infecção viral | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| EA201201031A1 (ru) | Ингибиторы вируса гепатита с | |
| BR112015023705A2 (pt) | composto da fórmula (ia) ou um sal, hidrato, solvato ou forma cristalina farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composto e método para síntese do composto da fórmula (ia) | |
| HRP20211622T1 (hr) | 4'-supstituirani nukleozidni-derivati kao inhibitori hiv reverzne transkriptaze | |
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| NZ739248A (en) | Inhibitors of hepatitis c virus | |
| PH12014501134B1 (en) | 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication | |
| BR112018011788A2 (pt) | formas sólidas de éster etílico de ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, seus sais e um método de preparação | |
| EP2590655A4 (en) | COMPOUNDS AND METHOD FOR INHIBITING PHOSPHATE TRANSPORT | |
| MX370141B (es) | Profármacos que comprenden un conjugado de ácido hialurónico enlazador agonista dual de glp-1/glucagón. | |
| BR112015008717A2 (pt) | composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii | |
| WO2011038234A3 (en) | Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions |